Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4FLUART
- Development stage
- Phase 1
- Lead developer
- Fluart Innovative Vaccines
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
4FLUART is an inactivated, adjuvanted, whole virion quadrivalent influenza vaccine (QIV) developed by Fluart Innovative Vaccine Ltd, Hungary. It is designed to provide protection against influenza by stimulating the immune system. The vaccine is administered intradermally and is currently being evaluated for its safe usability and immunogenicity in adult subjects.
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on 4FLUART.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4FLUART.